Jeff Bezos Is Funding a Wild Hunt for the Brain’s ‘Core Algorithm’

With $500 million in funding and a reported $2.5 billion valuation, Flourish wants to reinvent AI by putting real neurons ...
cmu.edu

Machine Learning & Data Science

Machine Learning now shapes how decisions are made, systems are built, and how work gets done. Building real understanding means learning the fundamentals from the faculty at the School of Computer ...
STAT

Merck’s RSV drug approval and a drug manufacturer winds down

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
Nasdaq

Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...
IEEE

Condensed recursive structures for computing multi-dimensional DCT with arbitrary length

Abstract: In this paper, the efficient recursive structure for computing arbitrary length M-dimensional (M-D) discrete cosine transform (DCT) is proposed. The M-D DCT are first converted into ...
health.economictimes.indiatimes

Nvidia-backed Recursion's shares fall on mixed data for rare disorder drug

London: Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...
IEEE

Recursive structure for linear filtering using number theoretic transform

Abstract: Where speed of computation, i.e. data throughput, is not a constraint, it is feasible to implement digital signal processing algorithms in a bit serial fashion. One could employ look-up ...
CNBC

We've built an unbiased platform that lets data drive decisions, not us, says Recursion CEO

Recursion Pharmaceuticals Co-Founder and CEO Chris Gibson joins 'Mad Money' host Jim Cramer to talk integrating machine learnings into drug development and partnering with Nvidia. Got a confidential ...